Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease

Expert Review of Respiratory Medicine

Volumn 10, Issue 10, 2016, Pages 1045-1055

  Radovanovic, Dejan ^a   Mantero, Marco ^a   Sferrazza Papa, Giuseppe Francesco ^b   Valenti, Vincenzo ^a   Aliberti, Stefano ^a   Di Marco, Fabiano ^b   Santus, Pierachille ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

Author keywords

bronchodilation; chronic obstructive pulmonary disease; fixed dose combination; Formoterol fumarate; glycopyrronium bromide; metered dose inhaler; porous particles

Indexed keywords

ACLIDINIUM BROMIDE; FORMOTEROL; FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM; INDACATEROL; OLODATEROL PLUS TIOTROPIUM BROMIDE; UMECLIDINIUM PLUS VILANTEROL; BRONCHODILATING AGENT; DRUG COMBINATION; FORMOTEROL FUMARATE; MUSCARINIC RECEPTOR BLOCKING AGENT;

ARTICLE; BACKACHE; BRONCHITIS; BRONCHODILATATION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; LONG TERM CARE; MANAGED CARE; MEDICATION COMPLIANCE; METABOLIC DISORDER; METERED DOSE INHALER; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; FORMOTEROL FUMARATE; GLYCOPYRROLATE; HUMANS; METERED DOSE INHALERS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84984690359     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2016.1227247     Document Type: Article

References (57)

1. P.Santus, D.Radovanovic, P.Paggiaro, et al. Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol. Eur J Intern Med. 2015;26(6):379–384.• A comprehensive review on LABA pharmacodynamics and their ancillary effects.
2. C.D.Mathers, D.Loncar Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
3. E.Diaz-Guzman, D.M.Mannino. Epidemiology and prevalence of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):7–16.
4. Global Initiative for Chronic Obstructive Pulmonary Disease,GOLD. Revision 2016. [cited 2016 Jun 2].
5. M.Cazzola, F.Di Marco, P.Santus, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther. 2004;17(1):35–39.
6. F.Di Marco, M.Verga, P.Santus, et al. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease:a pilot study. Resp Med. 2006;100(11):1925–1932.
7. L.Calzetta, P.Rogliani, M.G.Matera, et al. A Systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181–1196.
8. T.Van Der Molen, M.Cazzola. Beyond lung function in COPD management:effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Resp J. 2012;21(1):101–108.
9. D.P.Tashkin, J.Pearle, D.Iezzoni, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009;6:17–25.
10. M.Cazzola, L.Calzetta, A.Segreti, et al. Translational study searching for synergy between glycopyrronium and indacaterol. COPD. 2015;12(2):175–181.
11. L.Calzetta, M.G.Matera, M.Cazzola. Pharmacological interaction between LABAs and LAMAs in the airways:optimizing synergy. Eur J of Pharm. 2015;761:168–173.•• A pharmacological paper of striking interest and value.
12. M.Cazzola, M.Molimard. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. COPD Pulm Pharmacol Ther. 2010;23(4):257–267.• Important position paper on LABA/LAMA therapy in COPD.
13. S.Cohen, M.C.Miles, J.F.Donohue, et al. Dual therapy strategies for COPD:the scientific rationale for LAMA + LABA. Int J of COPD. 2016;11:785–797.
14. R.Vehring, D.Lechuga-Ballesteros, V.Joshi, et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28:15015−15023.
15. P.M.A.Calverley. COPD:what is the unmet need? Br J Pharmacol. 2008;155:487–493.
16. J.A.Wedzicha, D.Banerji, K.R.Chapman, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234.
17. A.Agusti, J.Hedner, J.M.Marin, et al. Night-time symptoms:a forgotten dimension of COPD. Eur Respir Rev. 2011;20(121):183–194.
18. A.Valipour, P.Lavie, H.Lothaller, et al. Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. Sleep Med. 2011;12:367–372.
19. N.Scichilone, A.Benfante, M.Bocchino, et al. Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases? Pulm Pharmacol Ther. 2015;31:63–67.
20. M.Cazzola, P.Rogliani, J.Ora, et al. Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2016;17(7):977–988.
21. C.Tantucci, D.Modina. Lung function decline in COPD. Int J of COPD. 2012;7:95–99.
22. M.Kendall, S.Buckingham, S.Ferguson, et al. Exploring the concept of need in people with very severe chronic obstructive pulmonary disease:a qualitative study. BMJ Support Palliat Care. 2015. doi:10.1136/bmjspcare-2015-000904.
23. Data from:U.S. Food and Drug Administration, label files, prescribing information. [cited 2016 Jun1]. Available from:http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist.
24. Data from:HIGHLIGHTS OF PRESCRIBING INFORMATION of Bevespi Aerosphere™; cited Apr 2016 3239006 5/16.
25. Data from:UK Medicines Information, [cited 2016 Jun1]. Available from:http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5371.
26. S.P.Newman. Principles of metered-dose inhaler design. Resp Care. 2005;50(9):1177−1190.
27. P.Rogueda. Novel hydrofluoroalkane suspension formulations for respiratory drug delivery. Exp Opin Drug Delivery. 2005;2(4):625−638.
28. R.H.Cummings. Pressurized metered dose inhalers:chlorofluorocarbon to hydrofluoroalkane transitionValve performance. J Allergy Clin Immunol. 1999;104(6):s230−s235.
29. D.Lechuga-Ballesteros, R.Vehring, S.K.Dwivedi. A new co-Suspension MDI platform:scientific foundations of mono, dual and triple combination products. Poster presented at the Respiratory Drug Delivery (RDD) meeting; 2011; Berlin (Germany). 1. 101–112
30. J.Vidya, B.Noga, D.Lechuga-Ballesteros, et al. Breaking microgram barrier to conduct dose ranging studies with long acting bronchodilators from a novel cosuspension metered dose inhaler product platform. Poster presented at the Annual Meeting of the European Respiratory Society. Vienna (Austria). Eur Resp J. 2012;40(Suppl 56):P2150.
31. R.Vehring, M.Hartman, R.Schultz et al. Glycopyrrolate and formoterol fumarate monotherapy and combination metered dose inhalers with high dose uniformity and stable aerosol properties. Poster presented at the Annual Meeting of the American Thoracic Society; 2010 14–19; New Orleans (LA).
32. S.Rennard, C.Fogarty, C.Reisner, et al. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2014;14:118.
33. R.H.Cummings, R.Schultz, J.H.Speck et al. Performance advantages of pearl cosuspension formulation technology for manufacturing of metered-dose inhalers. Poster presented at the Respiratory Drug Delivery (RDD) meeting; 2011 3–6; Berlin (Germany).
34. G.P.Anderson. Formoterol:pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci. 1993;52(26):2145–2160.
35. N.J.Carter. Inhaled glycopyrronium bromide:a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs. 2013;73:741–753.•• An impressive and meticulous review on glycopyrronium pharmacokinetics and pharmacodynamics.
36. R.Sechaud, D.Renard, L.Zhang-Auberson, et al. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther. 2012;50:118–128.
37. P.Santus, D.Radovanovic, F.Di Marco, et al. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study. Pulm Pharmacol Ther. 2015;35:42–49.• The first comprehensive physiopathological experimental evidence of in vivo onset of action of aclidinium and glycopyrronium.
38. C.Reisner, G.T.Ferguson, E.St. Rose, et al. Pearl Therapeutics’ combination lama/laba Mdi (gff-Mdi, Pt003) formulation of formoterol fumarate and glycopyrrolate provides similar systemic exposure to the individual mdi formulations administered alone in patients with COPD following 1-week dosing. Poster presented at the Annual Meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2012;185:A2926.
39. D.Quinn, J.P.Seale, C.Reisner, et al. A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD. Respir Med. 2014;108(9):1327–1335.
40. L.Fabbri, R.Rodriguez-Roisin, C.Orevillo, et al. Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparators. Poster presented at the Annual Meeting of the European Respiratory Society. Barcelona (Spain). Eur Resp J. 2013;42(Suppl 57):P759.
41. C.Reisner, C.J.Orevillo, C.Fernandez, et al. Pearl therapuetics’ combination lama/laba (gff mdi, Pt003) provides comparable safety as measured by 24-hour holter monitoring to its components (gp mdi, Pt001 and ff Mdi, Pt005) and Foradil® Aerolizer®. Poster presented at the Annual Meeting of the American Thoracic Society. Philadelphia (PN, USA). Am J Respir Crit Care Med. 2013;187:A1485.
42. F.J.Martinez, L.M.Fabbri, S.I.Rennard, et al. Cardiovascular safety profile of a novel lama/laba co-suspension technology fixed-Dose combination of glycopyrrolate/formoterol delivered by metered dose inhaler in patients with COPD:24-hour holter monitoring study. Poster presented at the Annual Meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6783.
43. P.Rogliani, L.Calzetta, Ora J, et al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Eur J Pharmacol. 2015;761:383–390.
44. C.Reisner, C.Fernandez, E.St. Rose, et al. Characterization of the dose response of pearl therapeutics’ lama mdi (gp mdi, Pt001) from 36 micrograms to 600 nanograms bid; results from an integrated analysis of phase IIb studies in patients with COPD. Poster presented at the Annual Meeting of the American Thoracic Society. Philadelphia (PN, USA). Am J Respir Crit Care Med. 2013;187:A4274.
45. C.Reisner, C.Fogarty, S.Spangenthal, et al. Novel combination of glycopyrrolate and formoterol mdi (gff-mdi) provides superior bronchodilation compared to its components administered alone, tiotropium dpi, and formoterol dpi in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD. Poster presented at the Annual Meeting of the American Thoracic Society. Denver (CO, USA). Am J Respir Crit Care Med. 2011;183:A6435.
46. C.Reisner, S.Rennard, C.Fogarty, et al. Pearl therapeutics’ combination lama/laba mdi (gff-mdi, Pt003) provides a significant benefit on home peak expiratory flow rate (pefr) and reduces the need for rescue albuterol use compared to its components administered alone, Spiriva® Handihaler®, and Foradil® Aerolizer® in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD. Poster presented at the Annual Meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2012;185:A2259.
47. C.Reisner, M.Gotfried, M.B.Denenberg, et al. Low doses of Pearl therapeutics’ lama/laba Combination mdi (gff mdi, Pt003) provide superior bronchodilation compared to components and to open-label spiriva handihaler in A Randomized, double-blind, placebo-controlled phase IIb study in patients with COPD. Poster presented at the Annual Meeting of the American Thoracic Society. Philadelphia (PN, USA). Am J Respir Crit Care Med. 2013;87:A2434.
48. C.Reisner, C.Orevillo, C.Fernandez, et al. Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development. Poster presented at the annual meeting of the European Respiratory Society. Barcelona (Spain). Eur Resp J. 2013;42(Suppl 57):P4153.
49. K.Rabe, F.Martinez, R.Rodriguez-Roisin, et al. PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPD. Poster presented at the annual meeting of the European Respiratory Society. Amsterdam (Nederland). Eur Respir J. 2015;46:PA4363.
50. F.J.Martinez, K.F.Rabe, R.Rodriguez-Roisin, et al. Pooled analyses from pinnacle-1 and −2:the novel lama/laba co-suspension technology glycopyrrolate/formoterol fixed-dose combination delivered by mdi shows improvement versus monocomponents in patients with COPD. Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6782.
51. F.J.Martinez, K.F.Rabe, R.Rodriguez-Roisin, et al. Beneficial effect of the novel lama/laba co-suspension technology of glycopyrrolate/formoterol fixed-dose combination delivered by mdi in gold A and B COPD patients:pooled analyses from Pinnacle-1 and −2. Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6785.
52. S.Arora, L.Delacruz, G.Feldman, et al. 24-hour lung function following the novel lama/laba co-suspension technology of glycopyrrolate/formoterol fixed-dose combination mdi, in patients with moderate-to-very-severe COPD. Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6792.
53. F.J.Martinez, L.M.Fabbri, G.T.Ferguson, et al. The novel LAMA/LABA co-suspension technology of glycopyrrolate/formoterol fixed-dose combination MDI significantly improves health status in symptomatic patients with COPD. Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6784.
54. N.A.Hanania, D.P.Tashkin, E.Kerwin, et al. Safety and efficacy of a novel lama/laba co-suspension technology glycopyrrolate/formoterol fixed-dose combination delivered by mdi:results of a one-year extension study in patients with COPD (pinnacle-3). Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6791.
55. C.Reisner, G.Gottschlich, F.Fakih, et al. 24-hour lung function profile of novel co-suspension technology glycopyrrolate/formoterol metered dose inhaler versus placebo and Spiriva® Respimat®, in patients with moderate-to-very-severe chronic obstructive pulmonary disease. Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6823.
56. G.T.Ferguson, K.F.Rabe, F.J.Martinez, et al. Pooled analyses from Pinnacle-1 and −2:safety profile of the novel lama/laba co-suspension technology fixed-dose combination (glycopyrrolate/formoterol) delivered by mdi, in patients with Chronic Obstructive Pulmonary Disease (COPD). Poster presented at the annual meeting of the American Thoracic Society. San Francisco (CA, USA). Am J Respir Crit Care Med. 2016;193:A6790.
57. S.P.Bhatt, X.Soler, X.Wang, et al. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194(2):178–184.